Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 EUR | -2.47% | -2.41% | -2.99% |
06/06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
05/06 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
Evolution of the average Target Price on I-Mab
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering I-Mab
Piper Sandler | |
Needham & Co. | |
HC Wainwright | |
SWS Research | |
Cantor Fitzgerald | |
Daiwa Securities |
EPS Revisions
- Stock Market
- Equities
- IMAB Stock
- 0VY Stock
- Consensus I-Mab